ELPA layperson events @EASL Congress
During the EASL Congress in Milan in June 2024, ELPA organised three layperson events dedicated to EU-funded medical projects in which ELPA is a partner.
The first event focused on GRIPonMASH, a project aiming to develop innovative screening strategies for managing metabolic-associated steatohepatitis (MASH). Participants learned about how the project aims to increase the number of patients diagnosed and aware of the lifestyle changes needed and decrease the number of people with MASH and liver cancer. In addition, they heard about the latest research findings, potential therapeutic approaches, and the project’s progress in improving patient outcomes. The session included presentations from leading researchers, interactive Q&A segments, and patient testimonials highlighting the real-world impact of the project.
The second event centred on MICROB-PREDICT, which investigates the role of the microbiome in predicting and treating liver diseases. Attendees were introduced to cutting-edge techniques to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis) when such decompensated cirrhosis progresses to acute-on-chronic liver failure (ACLF) and how to provide a patient’s individual treatment response. Based on such biomarkers, the project strives to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies. The event featured a panel discussion with microbiologists, hepatologists, and patient representatives, fostering a deeper understanding of the project’s objectives and its implications for future healthcare.
The third event highlighted LEOPARD, a project dedicated to enhancing liver transplantation outcomes by creating and validating an AI-based predictive algorithm, considering recently identified predictors, that surpasses current models in stratifying both decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC) patients by mortality/dropout risks on the waiting list. Experts in the field shared insights on how the project aims to improve patient outcomes by ensuring timely transplantations, harmonising European prioritisation schemes, and advocating for equitable access to liver transplantation to significantly reduce mortality on the waiting list.
These events not only provided valuable information to the lay audience but also emphasised the importance of patient engagement and advocacy in advancing medical research and improving healthcare outcomes. Through these interactive sessions, ELPA successfully bridged the gap between complex scientific research and patients’ everyday experiences, empowering attendees with knowledge and encouraging active participation in ongoing medical projects.